Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 86 results for hepatitis c

  1. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

    Clinical guideline
    Last updated
    3 December 2025
    View recommendations

    Sections for CG89

  2. How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested?

    for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of...

    Research recommendation
    Published
    9 June 2015

  3. Cirrhosis in over 16s: assessment and management (NG50)

    This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.

    NICE guideline
    Last updated
    8 September 2023
    View recommendations

    Sections for NG50

  4. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  5. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (HTG385)

    Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.

    HealthTech guidance
    Last updated
    17 January 2020
    View recommendations

    Sections for HTG385

  6. What are the most effective ways of involving people from groups at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are peer mentor programmes at increasing the number of people at increased risk who are tested and treated for hepatitis B and C?

    awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost...

    Research recommendation
    Published
    9 June 2015

  7. How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do...

    Research recommendation
    Published
    9 June 2015

  8. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do...

    Research recommendation
    Published
    9 June 2015

  9. What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?

    ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison? Any explanatory notes(if...

    Research recommendation
    Published
    9 June 2015

  10. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  11. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

    Medtech innovation briefing
    Published
    2 March 2015

  12. What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?

    Question What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the...

    Research recommendation
    Published
    9 June 2015

  13. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

    Clinical guideline
    Published
    24 February 2010
    View recommendations

    Sections for CG93

  14. How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?

    for hepatitis B and C? Any explanatory notes(if applicable) None. Source guidance details Comes from guidance...

    Research recommendation
    Published
    9 June 2015

  15. Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?

    communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the...

    Research recommendation
    Published
    9 June 2015